Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly ...

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help ...

They also follow a recent partnership with Costco, which began offering low-dose Ozempic and Wegovy for $499 per month out of ...

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting ...

The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the ...